[1] 薛媛,吕艳霞. 血清基质金属蛋白酶-3金属蛋白酶组织抑制剂-1水平与系统性红斑狼疮患者疾病活动指数评分的关联性探究[J]. 中国药物与临床,2020,20(19):3249-3251. [2] 李彬龙,师娜,刘婷. 重症急性胰腺炎患者血清SAA、CRP、ACE2水平变化及临床意义[J]. 海南医学,2021,32(15):1942-1945. [3] 丁峰,赵爱学. PCT、hs-CRP与Cys-C检测在PNS患儿中的诊断价值探讨[J]. 检验医学与临床,2021,18(2):264-266. [4] 张勇. 血清β2-MG水平对系统性红斑狼疮疾病活动度及合并肾损伤的评估价值[J]. 川北医学院学报,2021,36(5):644-647. [5] 中华医学会风湿病学分会,国家皮肤与免疫疾病临床医学研究中心,中国系统性红斑狼疮研究协作组. 2020中国系统性红斑狼疮诊疗指南[J]. 中华内科杂志,2020,59(3):172-185. [6] Romero-diaz J, Isenberg D, Ramsey-goldman R. Measures of adult systemic lupus erythematosus: updated version of British Isles Lupus Assessment Group (BILAG 2004), European Consensus Lupus Activity Measurements (ECLAM), Systemic Lupus Activity Measure, Revised (SLAM-R), Systemic Lupus Activity Questionnaire for Population Studies (SLAQ), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI)[J]. Arthritis Care Res (Hoboken), 2011, 11(1): 37-46. [7] Khwajia A.KDIGO clinical practice guidelines for acute kidney injury[J]. Nephron Clin Pract, 2012, 120(4): 179-184. [8] 惠保卫,何娜,王喆,等. 系统性红斑狼疮患者血清EpCAM,sB7-H3表达水平及其与疾病活动性的相关性研究[J]. 现代检验医学杂志,2022,37(6):24-27. [9] Lazar S, Kahlenberg JM.Systemic Lupus Erythematosus: New Diagnostic and Therapeutic Approaches[J]. Annu Rev Med, 2023, 74(27): 339-352. [10] Aringer M, Petri M.New classification criteria for systemic lupus erythematosus[J]. Curr Opin Rheumatol, 2020, 32(6): 590-596. [11] 张月凡,胡家骏,翟俊山. 急性胰腺炎患者血清CRP、IL-35和Presepsin水平变化及临床意义[J]. 中国病案,2021,22(4):102-106. [12] Karlsson J, Wettero J, Potempa LA, et al.Extracellular vesicles opsonized by monomeric C-reactive protein (CRP) are accessible as autoantigens in patients with systemic lupus erythematosus and associate with autoantibodies against CRP[J]. J Autoimmun, 2023, 139(1): 103073-103083. [13] 谢万红,王鼎,张珂. 血清淀粉样蛋白A、C反应蛋白检测对系统性红斑狼疮患者的意义[J]. 检验医学与临床,2021,18(24):3509-3512. [14] 贺建龙,马宁,朱彩艳. sdLDL-C、Cys-C、AT-Ⅲ在儿童原发性肾病综合征中的诊断价值[J]. 检验医学与临床,2022,19(11):1529-1531. [15] Fatemi A, Rahami Z, Smiley A.Role of Cystatin C in Predicting Disease Activity and Flare-Up in Systemic Lupus Erythematosus: A Longitudinal Follow-Up Study[J]. Int J Prev Med, 2021, 12(25): 63-73. [16] Baraka E, Hashaad N, Abdelhalim W, et al.Serum cystatin C and βeta-2 microglobulin as potential biomarkers in children with lupus nephritis[J]. Arch Rheumatol, 2022, 38(1): 56-66. [17] 高蔼萍,袁维. 血清sUA、sCys-C、Um-ALB/Cr在系统性红斑狼疮早期肾损伤患者中的诊断价值[J]. 临床医学研究与实践,2019,4(22):127-129. [18] 赵小莹,王喆,刘芯汝,等. β2-MG、HMGB1及OAS1与系统性红斑狼疮患者疾病严重程度及肾损害的相关性[J]. 热带医学杂志,2020,20(12):1605-1609. [19] You T, Lin XY, Zhang CH, et al.Correlation between serum β2-microglobulin level and systemic lupus erythematosus disease activity: A PRISMA-compliant meta-analysis[J]. Medicine (Baltimore), 2022, 101(39): e30594-e30604. [20] 胥兴丽,王仁峰. 系统性红斑狼疮早期肾损伤诊断及危险因素分析[J]. 中国实验诊断学,2021,25(3):344-347. [21] 田玉,杨玉淑,丁萌,等. 系统性红斑狼疮患者血清β2-MG、PGRN、Gas6水平与疾病严重程度和肾脏损害的关系研究[J]. 现代生物医学进展,2022,22(4):752-756. |